199 related articles for article (PubMed ID: 36604418)
21. The β-arrestin1/endothelin axis bolsters ovarian fibroblast-dependent invadosome activity and cancer cell metastatic potential.
Del Rio D; Masi I; Caprara V; Ottavi F; Albertini Petroni G; Salvati E; Trisciuoglio D; Giannitelli SM; Bagnato A; Mauri E; Spadaro F; Rosanò L
Cell Death Dis; 2024 May; 15(5):358. PubMed ID: 38777849
[TBL] [Abstract][Full Text] [Related]
22. YAP and endothelin-1 signaling: an emerging alliance in cancer.
Tocci P; Blandino G; Bagnato A
J Exp Clin Cancer Res; 2021 Jan; 40(1):27. PubMed ID: 33422090
[TBL] [Abstract][Full Text] [Related]
23. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
Gupta VG; Hirst J; Petersen S; Roby KF; Kusch M; Zhou H; Clive ML; Jewell A; Pathak HB; Godwin AK; Wilson AJ; Crispens MA; Cybulla E; Vindigni A; Fuh KC; Khabele D
Gynecol Oncol; 2021 Jul; 162(1):163-172. PubMed ID: 33867143
[TBL] [Abstract][Full Text] [Related]
24. Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis.
Gong H; Nie D; Huang Y; Li Z
Int J Gynecol Cancer; 2020 Oct; 30(10):1576-1582. PubMed ID: 32817083
[TBL] [Abstract][Full Text] [Related]
25. Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification.
Gasimli K; Raab M; Tahmasbi Rad M; Kurunci-Csacsko E; Becker S; Strebhardt K; Sanhaji M
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142803
[TBL] [Abstract][Full Text] [Related]
26. Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
Lee EK; Matulonis UA
Expert Opin Emerg Drugs; 2020 Jun; 25(2):165-188. PubMed ID: 32569489
[TBL] [Abstract][Full Text] [Related]
27. Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors through Suppressing NF-κB-Triggered SASP in Cancer-Associated Fibroblasts.
Jin P; Li X; Xia Y; Li H; Li X; Yang ZY; Wang Z; Xu C; Fang T; Zhou D; Xiong X; Wang SY; Xu S; Gao Q
Mol Cancer Ther; 2023 Apr; 22(4):447-458. PubMed ID: 36780236
[TBL] [Abstract][Full Text] [Related]
28. Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in
Färkkilä A; Rodríguez A; Oikkonen J; Gulhan DC; Nguyen H; Domínguez J; Ramos S; Mills CE; Pérez-Villatoro F; Lazaro JB; Zhou J; Clairmont CS; Moreau LA; Park PJ; Sorger PK; Hautaniemi S; Frias S; D'Andrea AD
Cancer Res; 2021 May; 81(10):2774-2787. PubMed ID: 33514515
[TBL] [Abstract][Full Text] [Related]
29. Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells.
Perez JM; Twigg CAI; Guan W; Thomas SN
J Am Soc Mass Spectrom; 2022 Feb; 33(2):242-250. PubMed ID: 34958553
[TBL] [Abstract][Full Text] [Related]
30. Appropriate Selection of PARP Inhibitors in Ovarian Cancer.
Smith M; Pothuri B
Curr Treat Options Oncol; 2022 Jun; 23(6):887-903. PubMed ID: 35412195
[TBL] [Abstract][Full Text] [Related]
31. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition.
Gabbasov R; Benrubi ID; O'Brien SW; Krais JJ; Johnson N; Litwin S; Connolly DC
Cancer Biol Ther; 2019; 20(7):1035-1045. PubMed ID: 30929564
[TBL] [Abstract][Full Text] [Related]
32. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
33. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
34. Targeting BRPF3 moderately reverses olaparib resistance in high grade serous ovarian carcinoma.
Bitler BG; Bailey CA; Yamamoto TM; McMellen A; Kim H; Watson ZL
Mol Carcinog; 2023 Nov; 62(11):1717-1730. PubMed ID: 37493106
[TBL] [Abstract][Full Text] [Related]
35. The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous
Gralewska P; Gajek A; Rybaczek D; Marczak A; Rogalska A
Cells; 2022 Jun; 11(12):. PubMed ID: 35741017
[TBL] [Abstract][Full Text] [Related]
36. Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis.
Bagnato A; Rosanò L
Cells Tissues Organs; 2007; 185(1-3):85-94. PubMed ID: 17587812
[TBL] [Abstract][Full Text] [Related]
37. Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines.
Fleury H; Carmona E; Morin VG; Meunier L; Masson JY; Tonin PN; Provencher D; Mes-Masson AM
Oncotarget; 2017 Jun; 8(25):40152-40168. PubMed ID: 27374179
[TBL] [Abstract][Full Text] [Related]
38. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells.
Rosanò L; Spinella F; Di Castro V; Nicotra MR; Dedhar S; de Herreros AG; Natali PG; Bagnato A
Cancer Res; 2005 Dec; 65(24):11649-57. PubMed ID: 16357176
[TBL] [Abstract][Full Text] [Related]
39. [Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients].
Wang DF; Zhang J; Zhang C; Yu J; Shi Y; Xu SQ; Fan Y; Zhou FZ; Song SQ; Liu H; Zhang GN
Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):641-652. PubMed ID: 36177575
[No Abstract] [Full Text] [Related]
40. The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
Wichmann C; Klotz DM; Zeiler HJ; Hilger RA; Grützmann K; Krüger A; Aust D; Wimberger P; Kuhlmann JD
Gynecol Oncol; 2020 Dec; 159(3):850-859. PubMed ID: 32980128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
